Vaxcyte, INC 8-K filings

Vaxcyte, Inc. reports the retirement of Heath Lukatch from its Board of Directors and the appointment of John Markels as a new Class II director.

Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, where key directors were re-elected and the appointment of Deloitte & Touche LLP as auditor was ratified.

Vaxcyte, Inc. has established a new 'at-the-market' equity offering program to sell up to $500 million of its common stock through Leerink Partners LLC.

Vaxcyte, Inc. announced its Q4 and full-year 2025 financial results, highlighting significant progress in its VAX-31 adult and infant clinical programs, manufacturing readiness, and a recent $600 million equity offering.

Vaxcyte, Inc. successfully completed a public offering of 12.65 million common shares, including the full exercise of an over-allotment option, generating approximately $600.2 million in net proceeds.

Vaxcyte, Inc. has amended its executive change in control and severance agreements, increasing severance multipliers for its CEO and other key officers to align with peer group levels.

Vaxcyte announced its third quarter 2025 financial results, positive final data from its VAX-24 infant Phase 2 study, and significant progress on its VAX-31 vaccine candidate, alongside a new manufacturing agreement and executive appointment.

Vaxcyte, Inc. has entered into a 15-year Master Services Agreement with Patheon Manufacturing Services LLC for drug product manufacturing and supply.

Vaxcyte reports Q2 2025 financial results, highlights VAX-31 clinical and regulatory progress, and extends cash runway to mid-2028.

Vaxcyte, Inc. announced the successful passage of all four proposals at its Annual Meeting of Stockholders held on June 12, 2025, including the re-election of Class II directors and the ratification of its independent accounting firm, though executive compensation received notable dissent.

Vaxcyte reports positive topline data from its Phase 2 dose-finding study of VAX-24 in healthy infants and provides a business update, highlighting progress across its pneumococcal conjugate vaccine (PCV) candidates.

Vaxcyte, Inc. appoints Dr. Olivier Brandicourt to its Board of Directors, effective May 1, 2025, granting him equity and compensation in accordance with the company's director compensation program.

Vaxcyte reports positive topline results from its Phase 2 dose-finding study of VAX-24 in healthy infants, showing a safety profile similar to Prevnar 20 and substantial immune responses.

Vaxcyte reports strong financial position with $3.1 billion in cash and advancements in its VAX-31 and VAX-24 vaccine programs, setting the stage for Phase 3 trials and data readouts.

Vaxcyte, Inc. has amended and restated its lease agreement to expand its headquarters to 258,581 square feet and subleased a portion of its existing space.

Vaxcyte reported positive topline data for its VAX-31 pneumococcal vaccine candidate in adults, selected it for Phase 3 development, and raised $1.4 billion through a public offering.

Vaxcyte, Inc. has successfully priced a public offering of common stock and pre-funded warrants, expected to generate net proceeds of $1.42 billion.

Vaxcyte's VAX-31 31-valent pneumococcal conjugate vaccine demonstrated positive safety, tolerability, and immunogenicity results in a Phase 1/2 study in adults aged 50 and older.

Vaxcyte reported its second quarter 2024 financial results, highlighted by a strong cash position and progress in its vaccine development programs, with key data readouts expected in the coming months.

Vaxcyte, Inc. has appointed John P. Furey as a Class II director and member of the Compensation Committee, effective July 2, 2024.

Vaxcyte, Inc. held its annual meeting of stockholders on June 6, 2024, where directors were re-elected and the company's auditor was ratified.

Vaxcyte announced its first quarter 2024 financial results, highlighted by the completion of enrollment in key clinical trials and a strong cash position following a successful public offering.

Vaxcyte reports significant advancements in its vaccine programs, including the completion of enrollment for the VAX-31 adult Phase 1/2 study and a strong cash position of $1.2 billion, excluding recent offering proceeds.

Vaxcyte, Inc. has successfully raised approximately $816.5 million through a public offering of common stock and pre-funded warrants, with underwriters fully exercising their option to purchase additional shares.